YBGJ Yubo International Biotech Ltd
Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 895464 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY68,727.8%
TTM net income YoY31.6%
TTM EPS YoY100.0%
Revenue 3-yr CAGR-73.4%
Net income 3-yr CAGR—
Margins
Gross margin66.1%
Operating margin-8,232.7%
Net margin-7,171.5%
FCF margin—
EBITDA margin-7,667.1%
Returns
ROE—
ROA-110.4%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets544.9%
Debt / equity—
Current ratio0.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.47x
Accruals ratio-58.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $12,353 | $0 | $0 | $0 | -$18 |
| Cost of revenue | $0 | $0 | $0 | $4,188 | $0 | $0 | $0 | -$5 |
| Gross profit | $0 | $0 | $0 | $8,165 | $0 | $0 | $0 | -$13 |
| Operating income | -$203,388 | -$238,860 | -$289,274 | -$285,468 | -$310,134 | -$249,699 | -$467,299 | -$357,298 |
| Interest expense | — | — | — | — | $18 | $23 | — | — |
| Pretax income | -$203,726 | -$268,721 | -$295,026 | -$285,651 | -$310,152 | -$249,722 | -$467,318 | -$352,886 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$188,376 | -$247,949 | -$272,608 | -$176,960 | -$276,771 | -$230,333 | -$435,630 | -$352,886 |
| EBITDA | -$202,738 | -$238,067 | -$263,529 | -$242,787 | -$268,241 | -$207,955 | -$425,676 | -$318,130 |
| EPS (diluted) | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 170.42M | 170.42M | 170.42M | — | 147.87M | 119.82M | 119.82M | — |
| Banking | ||||||||
| Net interest income | — | — | — | — | — | — | -$19 | — |
| Deposits | $74,238 | $79,207 | $68,500 | $71,135 | $69,792 | $69,792 | $68,500 | $68,500 |
| Balance sheet | ||||||||
| Cash & equivalents | $9,465 | $11,989 | $10,382 | $8,062 | $10,926 | $10,416 | $9,773 | $7,015 |
| Receivables | $123,473 | $138,052 | $134,220 | $138,043 | $114,287 | $118,006 | $146,687 | $164,984 |
| Inventory | $22,410 | $24,803 | $24,414 | $24,034 | $37,889 | $37,650 | $37,212 | $36,953 |
| Current assets | $579,352 | $583,098 | $597,823 | $667,512 | $649,563 | $659,102 | $685,162 | $682,751 |
| PP&E, net | $17,125 | $17,444 | $17,761 | $43,030 | $84,645 | $126,007 | $165,947 | $205,911 |
| Intangibles | $38,540 | $39,883 | $39,175 | $42,080 | $43,241 | $44,653 | $47,505 | $50,523 |
| Total assets | $651,391 | $672,272 | $709,872 | $847,094 | $953,211 | $1.05M | $1.17M | $1.53M |
| Current liabilities | $3.55M | $3.33M | $3.02M | $2.79M | $2.56M | $5.03M | $4.78M | $4.72M |
| Total liabilities | $3.55M | $3.33M | $3.02M | $2.79M | $2.56M | $5.03M | $4.81M | $4.83M |
| Shareholders' equity | -$2.85M | -$2.62M | -$2.30M | -$1.95M | -$1.66M | -$4.00M | -$3.67M | -$3.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$157 | -$84,104 | -$207,157 | -$128,752 | -$359,056 | -$14,028 | -$392,043 | -$932,711 |
| Capital expenditure | — | — | $0 | — | — | — | $6,186 | — |
| Free cash flow | — | — | -$207,157 | — | — | — | -$398,229 | — |
| Investing cash flow | $0 | $0 | $0 | -$79,904 | $0 | $86,090 | -$6,186 | $0 |
| Financing cash flow | $11,459 | $77,231 | $214,523 | $375,626 | $0 | $196,139 | $277,780 | $1.11M |
| Depreciation & amortization | $650 | $793 | $25,745 | $42,681 | $41,893 | $41,744 | $41,623 | $39,168 |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.